Matinas BioPharma Holdings, Inc. (MTNB)

Market Cap	4.09M +23.8%
Revenue (ttm)	n/a
Net Income	-11.23M
EPS	-1.93
Shares Out	6.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	322,046
Open	0.4838
Previous Close	0.5570
Day's Range	0.4838 - 0.6387
52-Week Range	0.4800 - 3.0900
Beta	1.62
Analysts	Hold
Price Target	30.00 (+4,602.93%)
Earnings Date	May 8, 2026

About MTNB

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as preventi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 2
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: MTNB
• Website: https://www.matinasbiopharma.com

Analyst Summary

According to one analyst, the rating for MTNB stock is "Hold" and the 12-month stock price target is $30.0.

Price Target

$30.0

(4,602.93% upside)

Analyst Consensus: Hold